Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ESRRG | P62508 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107624 | 0.82 | KMT2A (0.47) | LMNAHPGDSLC6A3KCNN4MAPT | |
| SCHEMBL8591431 | 0.82 | MAPT (0.54) | LMNAHSD17B10CA1CA2ALDH1A1 | |
| SCHEMBL31612944 | 0.82 | SMN1; SMN2 (0.47) | LMNAKCNN4ALDH1A1MAPTSRC | |
| SCHEMBL31612949 | 0.82 | SMN1; SMN2 (0.47) | LMNAKCNN4ALDH1A1MAPTSRC | |
| SCHEMBL8590506 | 0.82 | EPHX2 (0.41) | CYP3A4ESRRGLMNAHPGDTSHR | |
| SCHEMBL11465411 | 0.82 | KMT2A (0.52) | CYP3A4TSHRKCNN4ELANEMAPT | |
| SCHEMBL6689010 | 0.82 | KCNN4 (0.64) | ARTSHRKCNN4ALDH1A1ELANE | |
| SCHEMBL834511 | 0.82 | CHRM2 (0.53) | ESR1ESR2CYP3A4ESRRGTYR | |
| SCHEMBL595015 | 0.82 | KCNN4 (0.64) | ARTSHRKCNN4ALDH1A1ELANE | |
| SCHEMBL6684121 | 0.82 | KCNN4 (0.64) | ARTSHRKCNN4ALDH1A1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0374184-B1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE MEDICINE (US) | 1994-01-12 | — | — | EP | claimed |
| EP-0528975-A4 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | — | 1993-09-15 | — | — | EP | claimed |
| EP-0528975-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1993-03-03 | — | — | EP | claimed |
| WO-1993001824-A1 | COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS | BAYLOR COLLEGE OF MEDICINE (US) | 1993-02-04 | — | — | WO | claimed |
| WO-1991017749-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1991-11-28 | — | — | WO | claimed |
| EP-0374184-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. | BAYLOR COLLEGE MEDICINE (US) | 1990-06-27 | — | — | EP | claimed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | claimed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | INDENA S.P.A. (IT) | 2003-03-20 | — | — | US | disclosed |
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | INDENA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| WO-1993001824-A1 | COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS | BAYLOR COLLEGE OF MEDICINE (US) | 1993-02-04 | — | — | WO | disclosed |
| WO-1991017749-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1991-11-28 | — | — | WO | disclosed |
| WO-1991017749-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1991-11-28 | — | — | WO | disclosed |
| EP-0374184-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. | BAYLOR COLLEGE MEDICINE (US) | 1990-06-27 | — | — | EP | disclosed |
| EP-0374184-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. | BAYLOR COLLEGE MEDICINE (US) | 1990-06-27 | — | — | EP | disclosed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | disclosed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ESR1 775/4885ESR2 418/4885CYP3A4 812/4885 |
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | NFKBIA, MKI67, HPD | ESR1 3924/4885ESR2 3345/4885CYP3A4 2122/4885 |
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | HDGF, MKI67, HPD | ESR1 4792/4885ESR2 4654/4885CYP3A4 3482/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ESR1 775/4885ESR2 418/4885CYP3A4 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.